An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

Trial Profile

An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs TNO 155 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 01 May 2017 Planned End Date changed from 11 Feb 2020 to 18 Mar 2020.
    • 01 May 2017 Planned primary completion date changed from 11 Feb 2020 to 18 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top